“Order intake was marginally better than in the first quarter and in line with our expectations. The large projects in the market were still very few at the same time as demand was slow within the oil & gas and marine sectors. During the quarter external prognoses for the 2016 ship contracting were reduced to the range 650-850 from about 900. This is a low figure and in line with how we perceive the market. The order intake in the quarter was supported by a number of sectors, such as food. Geographically, the growth continued in Eastern Europe, including Russia. Excluding the Marine business, Asia also continued to grow with China as the main engine. Sequentially, the U.S. showed good growth, but compared to the same quarter last year the order intake is negatively impacted by the downturn within the oil & gas sector. The outcome per division was mixed. The operating margin in Process Technology continued to be burdened by a negative mix, which is expected to remain during the rest of the year. The Marine & Diesel division showed a flat order intake in the quarter, with a downturn in two segments at the same time as the demand within Pumping Systems grew. The profitability continued to be good. The Equipment division had a good quarter with good growth, especially in the food sector and in addition a stable operating margin. The strategic review that was announced in the previous quarter is continuing according to plan. The result of this review will be presented before the end of the year.” Tom Erixon, President and CEO Summary: second quarter Order intake decreased by 9 percent* to SEK 8,101 (9,146) million. Net sales decreased by 9 percent* to SEK 8,950 (10,177) million. Adjusted EBITA**: SEK 1,393 (1,816) million. Adjusted EBITA margin**: 15.6 (17.8) percent. Result after financial items: SEK 1,265 (1,455) million. Net income: SEK 931 (1,075) million. Earnings per share: SEK 2.21 (2.54). Cash flow from operating activities: SEK 1,233 (1,505) million. Impact on adjusted EBITA of foreign exchange effects: SEK 137 (182) million. Summary: first six months Order intake decreased by 14 percent* to SEK 15,811 (18,990) million. Net sales decreased by 8 percent* to SEK 17,149 (19,248) million. Adjusted EBITA**: SEK 2,726 (3,385) million. Adjusted EBITA margin**: 15.9 (17.6) percent. Result after financial items: SEK 2,355 (2,718) million. Net income: SEK 1,802 (1,938) million. Earnings per share: SEK 4.27 (4.59). Cash flow from operating activities: SEK 2,143 (2,606) million. Impact on adjusted EBITA of foreign exchange effects: SEK 230 (330) million. * Excluding currency effects. ** Alternative performance measures, defined on page 22. Outlook for the third quarter: “We expect that demand during the third quarter 2016 will be in line with or somewhat lower than in the second quarter.” Earlier published outlook (April 25, 2016): “We expect that demand during the second quarter 2016 will be on about the same level as in the first quarter.” The interim report has not been subject to review by the company's auditors. For more information, please contact: Peter Torstensson, Senior Vice President, Communications Phone: +46 46 36 72 31 Mobile: +46 709 33 72 31 peter.torstensson@alfalaval.com Gabriella Grotte, Investor Relations Manager Phone: +46 46 36 74 82 Mobile: +46 709 78 74 82 gabriella.grotte@alfalaval.com Alfa Laval AB (publ) PO Box 73 SE-221 00 Lund Sweden Corporate registration number: 556587-8054 This information is information that Alfa Laval AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at CET 11.45 on July 18, 2016.
Alfa Laval AB (publ) Interim report April 1 - June 30, 2016
Top 10 Most Recent News Articles
Tampa General's Food Bet Earns a 2026 Innovation Award
Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...
Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes
A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...
Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus
One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...
Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead
November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...
Continue Reading
Dallas College Recognition Signals Workforce Value
Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...
Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale
A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...
Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain
December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...
Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real
GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...
Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools
A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...
Continue Reading
Page Library Grant Makes a Practical Case for Access
A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...
Continue ReadingTop 5 Most Recently Viewed Articles
Seasonal Hiring Booms as Firms Eye Long-Term Talent
A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...
Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...
Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...
Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market
Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...
Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates
Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...
Continue Reading